Neurostimulation Devices – Market Insights – United States

The US neurostimulation device market is characterized by ongoing product innovation; iterative device improvements are regularly launching in established segments—such as the SCS and DBS device markets—while emerging novel products, such as closed-loop SCS devices and minimally invasive tibial nerve stimulation devices, are becoming available. Although the market continued to see a negative impact from the COVID-19 pandemic and hospital staffing shortages in 2022, it is positioned to expand strongly going forward, supported by rapid adoption of minimally invasive technologies and device use in expanding indications, such SCS treatment of painful diabetic neuropathy.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for neurostimulation devices in the US from 2019 through 2032.

The overall US neurostimulation device market is expected to see strong growth in upcoming years.

How strongly were neurostimulation device segments affected by lingering impacts of the COVID-19 pandemic in 2022?

Which device segments are anticipated to see the strongest growth going forward? Which factors will contribute to expansion?

New products in a number of device segments have entered the market recently.

Through which novel technologies are competitors differentiating their devices?

How will the entry of new technologies, such tibial nerve stimulation devices, impact volumes of other neurostimulation devices?

How is the launch of new products affecting the competitive landscape?

Competitors are targeting new indications.

Which companies have recently received expanded indication approvals in the SCS device market? How did approvals affect performance in 2022?

For which novel or expanded indications are competitors currently assessing devices?

Table of contents